Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00003670
First received: November 1, 1999
Last updated: June 6, 2012
Last verified: April 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2001
  Estimated Primary Completion Date: No date given